GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Shiller PE Ratio

Anika Therapeutics (Anika Therapeutics) Shiller PE Ratio : 38.76 (As of Apr. 29, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Shiller PE Ratio?

As of today (2024-04-29), Anika Therapeutics's current share price is $25.97. Anika Therapeutics's E10 for the quarter that ended in Dec. 2023 was $0.67. Anika Therapeutics's Shiller PE Ratio for today is 38.76.

The historical rank and industry rank for Anika Therapeutics's Shiller PE Ratio or its related term are showing as below:

ANIK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.96   Med: 33.21   Max: 69.32
Current: 38.76

During the past years, Anika Therapeutics's highest Shiller PE Ratio was 69.32. The lowest was 13.96. And the median was 33.21.

ANIK's Shiller PE Ratio is ranked worse than
67.03% of 276 companies
in the Medical Devices & Instruments industry
Industry Median: 26.93 vs ANIK: 38.76

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Anika Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-4.300. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.67 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anika Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Anika Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Shiller PE Ratio Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.17 31.73 24.18 21.64 34.03

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.64 22.22 21.03 16.09 34.03

Competitive Comparison of Anika Therapeutics's Shiller PE Ratio

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Shiller PE Ratio falls into.



Anika Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anika Therapeutics's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=25.97/0.67
=38.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Anika Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-4.3/129.4194*129.4194
=-4.300

Current CPI (Dec. 2023) = 129.4194.

Anika Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.970 99.695 1.259
201406 0.600 100.560 0.772
201409 0.400 100.428 0.515
201412 0.510 99.070 0.666
201503 0.230 99.621 0.299
201506 0.510 100.684 0.656
201509 0.550 100.392 0.709
201512 0.720 99.792 0.934
201603 0.450 100.470 0.580
201606 0.570 101.688 0.725
201609 0.590 101.861 0.750
201612 0.540 101.863 0.686
201703 0.370 102.862 0.466
201706 0.760 103.349 0.952
201709 0.460 104.136 0.572
201712 0.530 104.011 0.659
201803 -0.460 105.290 -0.565
201806 0.680 106.317 0.828
201809 0.530 106.507 0.644
201812 0.540 105.998 0.659
201903 0.310 107.251 0.374
201906 0.670 108.070 0.802
201909 0.640 108.329 0.765
201912 0.280 108.420 0.334
202003 0.400 108.902 0.475
202006 -0.540 108.767 -0.643
202009 -0.450 109.815 -0.530
202012 -1.100 109.897 -1.295
202103 0.200 111.754 0.232
202106 0.450 114.631 0.508
202109 0.040 115.734 0.045
202112 -0.400 117.630 -0.440
202203 -0.200 121.301 -0.213
202206 -0.200 125.017 -0.207
202209 -0.290 125.227 -0.300
202212 -0.340 125.222 -0.351
202303 -0.710 127.348 -0.722
202306 -0.190 128.729 -0.191
202309 -0.450 129.860 -0.448
202312 -4.300 129.419 -4.300

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anika Therapeutics  (NAS:ANIK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anika Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767